5-phenyl-1,2,4-triazine-3-carboxylic acid methyl ester | 36401-31-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: 5-phenyl-1,2,4-triazine-3-carboxylic acid methyl ester
• 英文别名: 5-Phenyl-1,2,4-triazin-3-carbonsaeure-methylester；Methyl 5-phenyl-1,2,4-triazine-3-carboxylate
• CAS: 36401-31-7
• 化学式: C₁₁H₉N₃O₂
• 分子量: 215.211
• InChiKey: CCWTXWIRVLKRRB-UHFFFAOYSA-N

物化性质

• 沸点：
  405.8±38.0 °C(Predicted)
• 密度：
  1.249±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  65
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-phenyl-1,2,4-triazine-3-carboxylic acid methyl ester 在 mercury(II) oxide 作用下， 以 苯 为溶剂， 反应 72.0h， 生成 7-(Dimethylaminomethylen)-3-phenyl-7H-cyclopentapyridin-1-carbonsaeure-methylester
  参考文献：
  名称：

  Neunhoeffer, Hans; Bachmann, Michael, Liebigs Annalen der Chemie, 1985, # 6, p. 1263 - 1271

  摘要：

  DOI：
• 作为产物：
  描述：

  苯基丙醇水合物 、 Oxalsaeure-methylester-amidrazon 生成 5-phenyl-1,2,4-triazine-3-carboxylic acid methyl ester 、 6-Phenyl-[1,2,4]triazine-3-carboxylic acid methyl ester
  参考文献：
  名称：

  4H和3H-氮杂环丁烷

  摘要：

  DOI：

  10.1016/s0040-4039(01)85566-0

文献信息

• Intramoleculare (4+2)-cycloadditionen mit inversem elektronenbedarf
  作者：H Schuster、J Sauer

  DOI：10.1016/s0040-4039(00)88268-4

  日期：1983.1

  1,2,4,5-Tetrazines, 1,2,4-triazines, α-pyrones and cyclopentadienones are reacted with bifunctional dienophiles 6 – 9 to yield semibullvalenes, snoutenes, azasnoutenes and polycyclic azo compounds or carbocycles in few steps.

  1,2,4,5-四嗪，1,2,4-三嗪，α-吡喃酮和环戊二烯酮与双官能亲二烯体6–9反应，可在几个步骤中生成半牛戊烯，古努烯，氮杂壬烯和多环偶氮化合物或碳环化合物。
• Ketenacetale als dienophile: Reaktivität und regiospezifität bei (4+2)-cycloadditionen mit inversem elektronenbedarf
  作者：K. Müller、J. Sauer

  DOI：10.1016/s0040-4039(01)81226-0

  日期：1984.1

  Ketene acetales 3a–3e differ in reactivity by 5–6 powers of ten in the reaction with monoaryl tetrazines 1a–1e. While 3a–3d yield “ortho-adducts” 4 almost exclusively, the ketene-N,N-acetale 3e give both regioisomers 4 and 5, the isomer ratio is depending on the polarity of the solvent used.

  在与单芳基四嗪1a-1e的反应中，乙缩醛3a-3e的反应性相差10-6的5-6次幂。3a-3d几乎完全生成“邻位加合物” 4，而烯酮-N，N-乙缩醛3e则同时生成区域异构体4和5，异构体比例取决于所用溶剂的极性。
• Ethynyltributyltin — a synthetic equivalent for acetylene, aryl, acyl and halogeno alkynes in [4+2] cycloadditions
  作者：Jürgen Sauer、Dieter K Heldmann

  DOI：10.1016/s0040-4039(98)00343-8

  日期：1998.4

  2,4-triazine-3-carboxyclic acid methyl ester 1 to furnish mainly 4-tributylstannyl-6-phenyl-pyridine-2-carboxyclic acid methyl ester 3a besides a small amount of the 3-tributylstannyl isomer 3b. The tributyltin substituent of pyridine 3a can be replaced by Pd-catalyzed acylation and arylation, by halogenation and protonation to yield functionalized pyridines 4 – 7, which are not available by direct

  乙炔基三丁基锡2环加到5-苯基-1,2,4-三嗪-3-羧酸甲酯1中，除少量3以外，主要提供4-三丁基锡烷基-6-苯基吡啶-2-羧酸甲酯3a。 -三丁基锡烷基异构体3b。吡啶3a的三丁基锡取代基可以被Pd催化的酰化和芳基化取代，可以通过卤化和质子化反应生成官能化的吡啶4-7，而相应的炔烃无法直接环加成。
• Pyridine Derivatives And Their Use In The Treatment Of Conditions Associated With Pathological Thrombus Formation
  申请人：SANOFI

  公开号：US20150141471A1

  公开（公告）日：2015-05-21

  The present invention relates to compounds of the formula (I), wherein the residues R 1 to R 6 , V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses. The compounds of the invention are effective antagonists of the platelet LPA receptor LPAR5 (GPR92) and can in general be applied in conditions in which an undesired activation of the platelet LPA receptor LPAR5, the mast cell LPA receptor LPAR5 or the microglia cell LPA receptor LPAR5 is present, or for the cure or prevention of which an inhibition of the platelet, mast cell or microglia cell LPA receptor LPAR5 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in medicaments, and pharmaceutical compositions comprising them.

  本发明涉及式（I）的化合物，其中残基R1至R6、V、G和M具有所述权利要求中指示的含义。式I的化合物是有价值的药理活性化合物，可用于治疗各种疾病，例如心血管疾病，如血栓栓塞疾病或再狭窄。本发明的化合物是血小板LPA受体LPAR5（GPR92）的有效拮抗剂，通常可用于存在血小板LPA受体LPAR5、肥大细胞LPA受体LPAR5或微胶质细胞LPA受体LPAR5的不良激活条件，或者用于治疗或预防需要抑制血小板、肥大细胞或微胶质细胞LPA受体LPAR5的情况。本发明还涉及制备式I化合物的方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的制药组合物。
• Cycloaddition Reactions with Azabenzenes, XVIII. Synthesis of [2]Pyrindines
  作者：Hans Neunhoeffer、Hans Neuhoeffer、Bernd Philipp、Brigit Schildhauer、Ralf Eckrich、Uwe Krichbaum

  DOI：10.3987/com-92-s(t)109

  日期：——

  The reaction of 1,2,4-triazines (1) and 1-cyclopentenylpyrrolidine (2) afforded 6,7-dihydro-5H-[2]-pyrindines (3) in good yields. Oxidation of 3 to the N-oxides (4), reaction of 4 with acetic anhydride to 5-acetoxy-6,7-dihydro-5H-[2]pyrindines (5) and elimination of acetic acid afforded [2]pyrindines (7). 2-Methyl-2H-[2]pyrindines (9) were also prepared.